United Therapeutics Co. (NASDAQ:UTHR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $388.25.

A number of analysts have weighed in on UTHR shares. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

United Therapeutics Stock Down 1.7 %

Shares of NASDAQ UTHR opened at $361.10 on Tuesday. The stock has a market cap of $16.12 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics has a 52-week low of $214.75 and a 52-week high of $417.82. The business has a 50-day moving average price of $362.68 and a 200 day moving average price of $360.45.

Insider Buying and Selling at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,164 shares of company stock worth $45,398,793 over the last quarter. 11.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Creative Planning boosted its stake in shares of United Therapeutics by 8.9% during the 3rd quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock worth $1,410,000 after acquiring an additional 322 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of United Therapeutics by 90.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 790 shares in the last quarter. Bleakley Financial Group LLC bought a new stake in shares of United Therapeutics during the 3rd quarter worth $240,000. Blue Trust Inc. boosted its stake in shares of United Therapeutics by 45.1% during the 3rd quarter. Blue Trust Inc. now owns 1,405 shares of the biotechnology company’s stock worth $503,000 after acquiring an additional 437 shares in the last quarter. Finally, Raymond James & Associates boosted its stake in shares of United Therapeutics by 1.7% during the 3rd quarter. Raymond James & Associates now owns 35,751 shares of the biotechnology company’s stock worth $12,811,000 after acquiring an additional 609 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.